A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants
FI Malik, LA Robertson, DR Armas, EP Robbie… - Basic to Translational …, 2022 - jacc.org
This phase 1, randomized, double-blind, placebo-controlled study of aficamten (formerly CK-3773274)
in healthy adults identified a pharmacologically active range of doses and …
in healthy adults identified a pharmacologically active range of doses and …
Evaluation of the effect of food and gastric pH on the single‐dose pharmacokinetics of cabozantinib in healthy adult subjects
…, J Grenier, D Swearingen, D Armas… - The Journal of …, 2015 - Wiley Online Library
Cabozantinib is a small molecule tyrosine kinase inhibitor that has been approved for the
treatment of patients with progressive, metastatic medullary thyroid cancer. Cabozantinib …
treatment of patients with progressive, metastatic medullary thyroid cancer. Cabozantinib …
[HTML][HTML] Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
…, J Meyer, W Zheng, S Rasmussen, D Armas… - International Journal of …, 2022 - Elsevier
Objectives A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 …
…, D Logan, K Lasseter, D Armas… - Diabetes, Obesity …, 2017 - Wiley Online Library
Aim To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single
and multiple doses of a novel, oral glucagon receptor antagonist, LGD‐6972, in healthy …
and multiple doses of a novel, oral glucagon receptor antagonist, LGD‐6972, in healthy …
Pharmacokinetic drug–drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer
…, A Mitselos, P Ward, J Jiao, D Armas… - Clinical …, 2020 - Springer
… Danielle Armas reports support from Janssen to her employer, Celerion, during the conduct
of the study. Peter Hellemans, Anna Mitselos, Peter Ward, James Jiao, and Caly Chien are …
of the study. Peter Hellemans, Anna Mitselos, Peter Ward, James Jiao, and Caly Chien are …
Atogepant has no clinically relevant effects on the pharmacokinetics of an ethinyl estradiol/levonorgestrel oral contraceptive in healthy female participants
…, MH Vallee, MF Dockendorf, D Armas… - The Journal of …, 2020 - Wiley Online Library
The incidence of migraine is higher among women than men and peaks during the reproductive
years, when contraceptive medication use is common. Atogepant, a potent, selective …
years, when contraceptive medication use is common. Atogepant, a potent, selective …
Identifying patients at risk for obstructive sleep apnea in a primary care practice
M Grover, M Mookadam, D Armas… - The Journal of the …, 2011 - Am Board Family Med
Purpose: The purpose of this study was to determine (1) whether our review of systems (ROS)
form facilitates identification of sleep complaints; (2) how frequently department physicians …
form facilitates identification of sleep complaints; (2) how frequently department physicians …
A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation
J Patrick, L Dillaha, D Armas, WC Sessa - Postgraduate medicine, 2015 - Taylor & Francis
Aims. Low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention reduces cardiovascular
disease mortality risk. ASA acetylates cyclooxygenase in the portal circulation and is …
disease mortality risk. ASA acetylates cyclooxygenase in the portal circulation and is …
Repeat Subcutaneous Administration of REGEN-COV® in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19
…, J Meyer, W Zheng, S Rasmussen, D Armas… - medRxiv, 2021 - medrxiv.org
Background Data show that a single dose of casirivimab and imdevimab (REGEN-COV ® )
is effective in treating hospitalized individuals and outpatients with COVID-19 and in post-…
is effective in treating hospitalized individuals and outpatients with COVID-19 and in post-…
First-in-human phase 1 study to assess safety, tolerability, and pharmacokinetics of a novel antifungal drug, VL-2397, in healthy adults
MP Mammen, D Armas, FH Hughes… - Antimicrobial Agents …, 2019 - Am Soc Microbiol
VL-2397 is an antifungal drug with a novel mechanism of action, rapid fungicidal in vitro activity,
and potent in vivo activity against Aspergillus fumigatus , including azole-resistant strains…
and potent in vivo activity against Aspergillus fumigatus , including azole-resistant strains…